Browsing Tag

PNH

Apellis and Sobi Report New Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI®…

Jason Junior Jun 10, 2022

WALTHAM, Mass. and STOCKHOLM, Sweden, June 10, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO:SOBI) today reported new analyses of Phase 3 studies that reinforce the robust efficacy and safety…

Health

Apellis Announces Seven Abstracts in PNH to be Presented at the European Hematology Association…

Jason Junior May 12, 2022

Accepted abstracts include an oral presentation highlighting quality of life improvements with EMPAVELI® (pegcetacoplan) WALTHAM, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global…

Health

Apellis and Sobi Receive Positive CHMP Opinion for Aspaveli® (pegcetacoplan) for the Treatment of…

Jason Junior Oct 15, 2021

WALTHAM, Mass. and STOCKHOLM, Sweden, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) announced today that the Committee for Medicinal Products for…

Health

Apellis Announces U.S. Food and Drug Administration (FDA) Approval of EMPAVELI™ (pegcetacoplan) for…

Jason Junior May 15, 2021

EMPAVELI, the first targeted C3 therapy, is approved for use in adults with PNH who are:Treatment naïveSwitching from C5 inhibitor Soliris® (eculizumab) Switching from C5 inhibitor Ultomiris® (ravulizumab) EMPAVELI was superior to…